Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients

Overview

Journal Ann Transplant

Specialty General Surgery

Date 2021 Mar 12

PMID 33707409

Citations 8

Authors

Nuri Baris Hasbal

Didem Turgut

Ebru Gok Oguz

Sena Ulu

Ozkan Gungor

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 19 (COVID-19) has been an ongoing pandemic since December 2019. Unfortunately, kidney transplant recipients are a high-risk group during the disease course, and scientific data are still limited in this patient group. Beyond the dosage of immunosuppressive drugs, pharmacological immunosuppression may also alter the infection response in the COVID-19 course. The effects of immunosuppressive agents on the development and process of infection should not be decided only by determining how potent they are and how much they suppress the immune system; it is also thought that the direct effect of the virus, increased oxidative stress, and cytokine storm play a role in the pathogenesis of COVID-19 disease. There are data about immunosuppressive drugs like calcineurin inhibitors (CNI) or mammalian target of rapamycin inhibitors (mTORi) therapy related to their beneficial effects during any infection course. Limited data suggest that the use of CNI or mTORi may have beneficial effects on the process. In this hypothetical review, the probable impacts of CNI and mTORi on the pathogenesis of the COVID-19 were investigated.

Citing Articles

Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK.

Maiese K Cells. 2023; 12(22).

PMID: 37998330 PMC: 10670256. DOI: 10.3390/cells12222595.

Cognitive Impairment in Multiple Sclerosis.

Maiese K Bioengineering (Basel). 2023; 10(7).

PMID: 37508898 PMC: 10376413. DOI: 10.3390/bioengineering10070871.

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.

Xue Y, Mei H, Chen Y, Griffin J, Liu Q, Weisberg E MedComm (2020). 2023; 4(3):e254.

PMID: 37193304 PMC: 10183156. DOI: 10.1002/mco2.254.

SARS-CoV-2 in immunocompromised individuals.

DeWolf S, Laracy J, Perales M, Kamboj M, van den Brink M, Vardhana S Immunity. 2022; 55(10):1779-1798.

PMID: 36182669 PMC: 9468314. DOI: 10.1016/j.immuni.2022.09.006.

Rapamycin golden jubilee and still the miraculous drug: a potent immunosuppressant, antitumor, rejuvenative agent, and potential contributor in COVID-19 treatment.

Mohamed M, Elkhateeb W, Daba G Bioresour Bioprocess. 2022; 9(1):65.

PMID: 35730039 PMC: 9188914. DOI: 10.1186/s40643-022-00554-y.

References

Muhlbacher F, Neumayer H, Del Castillo D, Stefoni S, Zygmunt A, Budde K . The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study. Transpl Int. 2013; 27(2):176-86. DOI: 10.1111/tri.12228. View

Poulsen N, von Brunn A, Hornum M, Blomberg Jensen M . Cyclosporine and COVID-19: Risk or favorable?. Am J Transplant. 2020; 20(11):2975-2982. PMC: 7436557. DOI: 10.1111/ajt.16250. View

Banerjee D, Popoola J, Shah S, Chis Ster I, Quan V, Phanish M . COVID-19 infection in kidney transplant recipients. Kidney Int. 2020; 97(6):1076-1082. PMC: 7142878. DOI: 10.1016/j.kint.2020.03.018. View

Wang S, Tseng S, Yen C, Yang J, Tsao C, Shen C . Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014; 451(2):208-14. PMC: 7092860. DOI: 10.1016/j.bbrc.2014.07.090. View

Treska V, Kobr J, Hasman D, Racek J, Trefil L, Reischig T . Ischemia-reperfusion injury in kidney transplantation from non-heart-beating donor--do antioxidants or antiinflammatory drugs play any role?. Bratisl Lek Listy. 2009; 110(3):133-6. View

Xie X, Jiang Y, Lai X, Xiang S, Shou Z, Chen J . mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. BMC Nephrol. 2015; 16:91. PMC: 4486141. DOI: 10.1186/s12882-015-0078-5. View

Traitanon O, Mathew J, La Monica G, Xu L, Mas V, Gallon L . Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells. PLoS One. 2015; 10(6):e0129658. PMC: 4472515. DOI: 10.1371/journal.pone.0129658. View

Herrera-Gomez F, Vasquez-Seoane M, Del Aguila W, Martin-Garcia D, Maurtua-Briseno Meiggs A, Gonzalez-Lopez A . Peripheral blood regulatory T cell counts as a predictive biomarker for the outcome of kidney transplant: A systematic review. Med Clin (Barc). 2017; 149(12):523-535. DOI: 10.1016/j.medcli.2017.05.008. View

Cvetkovic T, Velickovic-Radovanovic R, Stojanovic D, Stefanovic N, Ignjatovic A, Stojanovic I . Oxidative and Nitrosative Stress in Stable Renal Transplant Recipients with Respect to the Immunosuppression Protocol - Differences or Similarities?. J Med Biochem. 2017; 34(3):295-303. PMC: 4922351. DOI: 10.2478/jomb-2014-0047. View

10.

Lehrer S . Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review). World Acad Sci J. 2020; 2(3). PMC: 7170270. DOI: 10.3892/wasj.2020.42. View

11.

Mouy R, Stephan J, Pillet P, Haddad E, Hubert P, Prieur A . Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996; 129(5):750-4. DOI: 10.1016/s0022-3476(96)70160-9. View

12.

Iwasaki K, Kitahata N, Miwa Y, Uchida K, Matsuoka Y, Horimi K . Suppressive Effect of Everolimus on IL-2, IL-10, IL-21, and IFNγ Levels: Implications for the Successful Minimization of Calcineurin Inhibitor Use in Transplantation. Ther Drug Monit. 2019; 41(3):371-375. DOI: 10.1097/FTD.0000000000000630. View

13.

Nashan B, Gaston R, Emery V, Saemann M, Mueller N, Couzi L . Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012; 93(11):1075-85. DOI: 10.1097/TP.0b013e31824810e6. View

14.

Dawson T, Steiner J, Dawson V, Dinerman J, Uhl G, Snyder S . Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A. 1993; 90(21):9808-12. PMC: 47661. DOI: 10.1073/pnas.90.21.9808. View

15.

Ruscitti P, Berardicurti O, Iagnocco A, Giacomelli R . Cytokine storm syndrome in severe COVID-19. Autoimmun Rev. 2020; 19(7):102562. PMC: 7252135. DOI: 10.1016/j.autrev.2020.102562. View

16.

Lim W, Eris J, Kanellis J, Pussell B, Wiid Z, Witcombe D . A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transplant. 2014; 14(9):2106-19. DOI: 10.1111/ajt.12795. View

17.

Pascual J, Berger S, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y . Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol. 2018; 29(7):1979-1991. PMC: 6050928. DOI: 10.1681/ASN.2018010009. View

18.

Delgado-Roche L, Mesta F . Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection. Arch Med Res. 2020; 51(5):384-387. PMC: 7190501. DOI: 10.1016/j.arcmed.2020.04.019. View

19.

Aveles P, Criminacio C, Goncalves S, Bignelli A, Claro L, Siqueira S . Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation. Nephron Clin Pract. 2010; 116(4):c294-9. DOI: 10.1159/000318792. View

20.

Zadrazil J, Strebl P, Krejci K, Horcicka V, Horak P, Vostalova J . Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation. Clin Biochem. 2010; 43(6):559-65. DOI: 10.1016/j.clinbiochem.2010.01.003. View